share_log

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

Recursion Pharmaceuticals | 144:擬議出售證券
美股sec公告 ·  04/17 04:11
牛牛AI助理已提取核心訊息
Recursion Pharmaceuticals, Inc. Director Blake Borgeson is set to sell 11,447 Class A shares of the company on 04/16/2024, as per the latest filing. These shares, valued at approximately $87,725, were originally acquired as founders shares on 09/01/2016 as part of compensation from the issuer. This upcoming transaction follows a series of sales over the past three months, where Borgeson sold a total of 103,110 shares, generating gross proceeds of $1,124,868.48.
Recursion Pharmaceuticals, Inc. Director Blake Borgeson is set to sell 11,447 Class A shares of the company on 04/16/2024, as per the latest filing. These shares, valued at approximately $87,725, were originally acquired as founders shares on 09/01/2016 as part of compensation from the issuer. This upcoming transaction follows a series of sales over the past three months, where Borgeson sold a total of 103,110 shares, generating gross proceeds of $1,124,868.48.
根據最新文件,Recursion Pharmicals, Inc.董事布萊克·博格森定於2024年4月16日出售該公司的11,447股A類股票。這些股票價值約87,725美元,最初是作爲發行人薪酬的一部分於2016年1月9日作爲創始人股票收購的。這筆即將進行的交易是在過去三個月進行的一系列銷售之後進行的,博格森共出售了103,110股股票,總收益爲1,124,868.48美元。
根據最新文件,Recursion Pharmicals, Inc.董事布萊克·博格森定於2024年4月16日出售該公司的11,447股A類股票。這些股票價值約87,725美元,最初是作爲發行人薪酬的一部分於2016年1月9日作爲創始人股票收購的。這筆即將進行的交易是在過去三個月進行的一系列銷售之後進行的,博格森共出售了103,110股股票,總收益爲1,124,868.48美元。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。